Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Blood type (non-human) Ideally, cross-matching should be performed prior to transfusion, or a universal donor may be used. The ideal universal whole blood donor is a non-thoroughbred gelding that is Aa, Ca, and Qa negative. If this is not available, a gelding, preferably of the same breed as the patient, may be used as a donor, and cross-matching may be crudely accessed by mixing donor serum with patient blood. If the mixture agglutinates, the donor blood contains antibodies against the blood of the patient, and should not be used. The polymorphic systems in cattle include the A, B, C, F, J, L, M,